NIRAMAI has developed a novel breast cancer screening solution that uses Thermalytix.
Breast Cancer is the leading type of cancer in women. According to WHO, one in every 8 women in US is at the risk of developing a breast abnormality in her life time. It is well-established that early diagnosis is very critical in saving a life of a cancer patient. They at NIRAMAI have developed a new cancer screening software that uses machine intelligence over thermography images to enable a low cost, easy to use, portable solution and requires minimal human supervision. Their solution can detect cancer at a much earlier stage than traditional diagnostic methods and self-examination and can therefore improve survival rates. Their method of breast cancer screening can detect tumors 5 times smaller than what clinical exam can detect, is non-contact, painless and free of any radiation, apart from being low-cost, and universally accessible. With their solution, women of all age groups can undergo frequent screening without any side-effects.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 24, 2017 | Seed | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
500 Global | — | Seed |